AgingResearch.NewsJoin free

Oricula Therapeutics

CompanyUnited StatesFounded 2013

Wikidata

Oricula Therapeutics develops one asset, in phase 2 (ORC-13661 in drug-induced ototoxicity). Mostly small molecule; based in the United States, founded in 2013.

1
Asset
Furthest stage
Phase 2
0
Trials
0
Signals

Pipeline

1

  • ORC-13661

    Small molecule hair-cell protectant preventing aminoglycoside-induced ototoxicity.

    Phase 2, Small molecule, drug-induced ototoxicity

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Trials1

Intelligence